Gliomas are the most common primary brain tumors, typically managed with surgical resection followed by chemo‐ and/or radiation therapies as part of the standard of care.[7] Investigational targeted therapies have shown promise in some cases, yet few have been validated through clinical trials.[8] Mutations in isocitrate dehydrogenase (IDH) genes define the subclass of gliomas that display overall lower malignancy and better prognosis. This evidence concerns the gene IDH1 and central nervous system cancer.